Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review)

Experimental and Therapeutic Medicine

Volumn 3, Issue 1, 2012, Pages 9-14

  Zhang, Xiang ^a   Zhang, Wei ^a   Cao, Wei Dong ^a   Cheng, Gang ^b   Zhang, Yong Qiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Genetics; Glioblastoma multiforme; Malignant glioma; Molecular Markers; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARMUSTINE; LOMUSTINE; TEMOZOLOMIDE; TUMOR MARKER;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; GENE MUTATION; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PATIENT CARE; REVIEW; STEREOTACTIC RADIOSURGERY; TUMOR CELL; TUMOR DIAGNOSIS;

EID: 84855407859     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.367     Document Type: Review

References (61)

1. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
4. CBTRUS: Statistical report: primary brain tumors in the United States, 2000-2004. Central brain tumor registry of the United States, Chicago, 2008.
5. Clarke J, Butowski N and Chang SR: Recent advances in therapy for glioblastoma. Arch Neurol 67: 279-283, 2010.
6. Schmidinger M, Linzmayer L, Becherer A, et al: Psychometric-and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol 63: 55-61, 2003.
7. The Cancer Genome Atlas (TCGA) Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
8. Von Deimling A, Louis DN and Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
9. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P and Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223, 1996.
10. Steck PA, Lin H, Langford LA, et al: Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24: 135-143, 1996.
11. Brat DJ and van Meir EG: Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84: 397-405, 2004.
12. Fujisawa H, Reis RM, Nakamura M, et al: Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80: 65-72, 2000.
13. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010.
14. Schmidt MC, Antweiler S, Urban N, et al: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61: 321-328, 2002.
15. Albarosa R, Colombo BM, Roz L, et al: Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 58: 1260-1267, 1996.
16. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
17. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL and Park JW: Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32: 1185-1196, 2002.
18. Bleeker FE, Lamba S, Leenstra S, et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11, 2009.
19. Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P and Ohgaki H: p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol 56: 1236-1241, 1997.
20. Rasheed BK, McLendon RE, Friedman HS, et al: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10: 2243-2246, 1995.
21. Kil IS, Kim SY, Lee SJ and Park JW: Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs. Free Radic Biol Med 43: 1197-1207, 2007.
22. Dohrmann GJ, Farwell JR and Flannery JT: Glioblastoma multiforme in children. J Neurosurg 44: 442-448, 1976.
23. Sure U, Rüedi D, Tachibana O, et al: Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56: 782-789, 1997.
24. Suri V, Das P, Pathak P, et al: Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 11: 274-280, 2009.
25. Rood BR and MacDonald TJ: Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol 75: 267-272, 2005.
26. Shah N, Lin B, Sibenaller Z, et al: Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6: e16146, 2011.
27. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
28. Palanichamy K, Erkkinen M and Chakravarti A: Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 7: 490-504, 2006.
29. Prados MD and Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1-10, 2000.
30. Freije WA, Castro-Vargas FE, Fang Z, et al: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510, 2004.
31. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006.
32. Watanabe K, Sato K, Biernat W, et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530, 1997.
33. Adamson C, Kanu OO, Mehta AI, et al: Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18: 1061-1083, 2009.
34. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
35. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 70: 1445-1453, 2007.
36. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
37. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17: 98-110, 2010.
38. Grossman SA and Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31: 635-644, 2004.
39. Kanu OO, Mehta A, Di C, et al: Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13: 701-718, 2009.
40. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 25: 1-7, 2005.
41. Krex D, Klink B, Hartmann C, et al: Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606, 2007.
42. Xie D, Zeng YX, Wang HJ, et al: Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol 110: 481-489, 2005.
43. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
44. Mineo JF, Bordron A, Baroncini M, et al: Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir 149: 245-252, 2007.
45. Glas M, Happold C, Rieger J, et al: Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27: 1257-1261, 2009.
46. McLendon RE and Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98: 1745-1748, 2003.
47. Liu YH, Shete S, Etzel CJ, et al: Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 28: 2467-2474, 2010.
48. Steinbach JP, Blaicher HP, Herrlinger U, et al: Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 66: 239-242, 2006.
49. DeAngelis LM: Chemotherapy for brain tumors-a new beginning. N Engl J Med 352: 1036-1038, 2005.
50. McDermott MW, Sneed PK and Gutin PH: Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 14: 79-87, 1998.
51. Liu BL, Cheng JX, Zhang X and Zhang Wei: Controversies concerning the application of brachytherapy in central nervous system tumors. J Cancer Res Clin Oncol 136: 173-185, 2010.
52. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995.
53. Sathornsumetee S and Rich JN: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 6: 1087-1104, 2006.
54. Chi AS, Sorensen AG, Jain RK and Batchelor TT: Angiogenesis as a therapeutic target in malignant Gliomas. Oncologist 14: 621-636, 2009.
55. Jain RK: A new target for tumor therapy. N Engl J Med 360: 2669-2671, 2009.
56. Wen PY: Therapy for recurrent high-grade gliomas: does continuous dose-Intense temozolomide have a role? J Clin Oncol 28: 2051-2057, 2010.
57. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2009.
58. Moustakas A and Kreisl TN: New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Oncol Targets Ther 3: 27-38, 2010
59. Sathornsumetee S and Rich JN: Designer therapies for glioblastoma multiforme. Ann NY Acad Sci 1142: 108-132, 2008.
60. Luther N, Cheung NK, Souliopoulos EP, et al: Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther 9: 1039-1046, 2010.
61. Iwadate Y, Matsutani T, Hasegawa Y, et al: Selection of chemotherapy for glioblastoma expressing O6-methyltransferase. Exp Ther Med 1: 53-57, 2010.